ADRA2A基因型与儿童右美托咪定镇静剂量关联的初步研究
结果发现CC、GC、GG基因型组间最大和平均右美托咪定剂量均无差异,未能证实成人中ADRA2A多态性与右美托咪定反应的相关性,提示需在儿科人群中验证成人药物基因组学发现。
要点
- 儿童中ADRA2A基因型与右美托咪定剂量无显著关联。
- 成人PGx结论不能直接外推至儿科,需儿科验证。
核心结论
- 在儿科患者中,ADRA2A基因型与右美托咪定剂量无显著关联,未能重复成人研究结果。
主要发现
- 最大右美托咪定剂量(mCg/kg/h)在CC组(1,0.3-1.2)、GC组(1,0.3-1.3)和GG组(0.8,0.3-1.2)间无差异(p=0.37)。
- 平均右美托咪定剂量在CC组0.68(0.24-1.07)、GC组0.72(0.22-0.98)、GG组0.58(0.3-0.94)间无差异(p=0.67)。
临床怎么用
- 目前不建议根据ADRA2A基因型调整儿科右美托咪定剂量。
- 成人药物基因组学发现需在儿科人群中验证后方可应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Dexmedetomidine is titrated to achieve sedation in the pediatric and cardiovascular intensive care units (PICU and CVICU). In adults, dexmedetomidine response has been associated with an ADRA2A polymorphism (rs1800544); CC genotype is associated with an increased sedative response compared with GC and GG. To date, this has not been studied in children. DESIGN: We conducted a pilot study to determine whether ADRA2A genotype is associated with dexmedetomidine dose in children. MEASUREMENTS AND MAIN RESULTS: Forty intubated PICU or CVICU patients who received dexmedetomidine as a continuous infusion for at least 2 days were genotyped for ADRA2A with a custom-designed TaqMan® Assay. Ten (25%) subjects were wildtype (GG), 15 (37.5%) were heterozygous (GC), and 15 (37.5%) were homozygous (CC) variant. The maximum dexmedetomidine doses (mCg/kg/h) were not different between genotype groups CC (1, 0.3-1.2), GC (1, 0.3-1.3), and GG (0.8, 0.3-1.2), (p = 0.37); neither were mean dexmedetomidine doses for these respective genotype groups 0.68 (0.24-1.07), 0.72 (0.22-0.98), 0.58 (0.3-0.94), (p = 0.67). CONCLUSIONS: These findings did not confirm the results from adult studies where ADRA2A polymorphisms correlate with dexmedetomidine response, therefore highlighting the need for pediatric studies to validate PGx findings in adults prior to implementation in pediatrics.
引用
- Gallaway KA, Skaar TC, Biju A, et al. A pilot study of ADRA2A genotype association with doses of dexmedetomidine for sedation in pediatric patients. Pharmacotherapy. 2022. PMID: 35429176. doi:10.1002/phar.2684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。